10:02 AM EST - Paladin Labs Inc. : and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement. Paladin Labs Inc.
shares T.PLB are trading even at $40.49.
